Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5 Mcg, Vilanterol 25 Mcg, and Umeclidinium/Vilanterol 62.5/25 Mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5 Mcg, Vilanterol 25 Mcg, and Umeclidinium/Vilanterol 62.5/25 Mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary) ; Vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 07 Jan 2016 Results of pooled analysis of two identical phase III studies published in the Respiratory Medicine.
    • 24 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top